| abstract |
Provided herein are methods and compositions directed to modified proteins of the anti-Mullerian hormone (AMH) for regulating follicle formation in women, particularly follicle activation and maturation and immature (primitive) follicle depletion. In certain embodiments, modulating or inhibiting follicle formation in a woman treats, stops or slows ovarian aging, and/or onset of menopause and/or symptoms associated with menopause, induced by gonadotoxic treatment. delayed premature ovarian decline, or a disease or condition caused by genetic mutations in genes that regulate follicle formation and ovarian biology. |